改善经导管动脉化疗栓塞术疗效的临床及基础研究进展  

Advances in clinical and fundamental researches for improving the efficacy of transcatheter arterial chemoembolization

作　　者：夏子聪 赵辉[1] XIA Zicong;ZHAO Hui(Department of Interventional Radiology,Affiliated Hospital of Nantong University,Nantong,Jiangsu Province 226001,China)

机构地区：[1]南通大学附属医院介入放射科,江苏南通226001

出　　处：《介入放射学杂志》2023年第7期705-709,共5页Journal of Interventional Radiology

摘　　要：经导管动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)常用于中晚期肝细胞癌(HCC)的一线治疗。但是由于HCC的异质性、富血管的特点以及耐药等原因,部分患者并不能从TACE中获益。近年来,为了延长中晚期HCC患者的生存期,对于改善TACE疗效策略的研究不断推进。新的栓塞材料可以增强TACE栓塞效果延缓药物释放,联合其他综合治疗,改善TACE后异常的HCC微环境,可以减少TACE后的复发率并延长生存期。随着基础研究的深入以及基础临床转化,影响TACE疗效的相关危险因素以及应对方法被不断发现和验证。Transcatheter arterial chemoembolization(TACE)is often used as the first-line treatment for mid-advanced hepatocellular carcinoma(HCC).However,due to the heterogeneity of HCC,blood-rich features and drug-resistance of the tumor,etc.some patients are not able to get benefits from TACE.In recent years,researches on the strategies of improving the efficacy of TACE have continuously prolong the survival time of patients with mid-advanced HCC.The newly-developed embolization materials can enhance the embolization effect of TACE as well as delay the drug release.Comprehensive treatment with other therapies to improve the post-TACE anomalous microenvironment of HCC can reduce the recurrence rate and prolong survival after TACE.With the deepening of basic research and basic clinical transformation,the related risk factors affecting TACE efficacy are constantly discovered,and their coping approaches are constantly validated.(J Intervent Radiol,2023,32:705-709)

关 键 词：肝细胞癌 经导管动脉化疗栓塞术 药物洗脱微球 放疗 免疫治疗 靶向治疗 缺氧诱导因子1Α 

分 类 号：R735.7[医药卫生—肿瘤]